Latest News
Conference Coverage
Future of NASH care means multiple targets, multiple providers, expert says
PHILADELPHIA – While current options are limited, newer treatments targeting different aspects of NASH pathogenesis could improve long-term...
Conference Coverage
Studies link TMAO to microbiome, reveal new heart disease target
MIAMI – TMAO alters cholesterol and bile acid metabolism, upregulates inflammatory pathways, and promotes foam cell formation, all of which worsen...
News
New renal, CV disease indication sought for canagliflozin
Canagliflozin is currently indicated for patients with type 2 diabetes but may soon help treat those who also have chronic kidney disease.
Conference Coverage
Sperm quality linked to some recurrent pregnancy loss
NEW ORLEANS – Male partners, who are often ignored in the evaluation of recurrent pregnancy loss, may have a contributing role in some cases of...
Conference Coverage
CPAP use associated with greater weight loss in obese patients with sleep apnea
NEW ORLEANS – CPAP use was associated with a higher level of weight loss in obstructive sleep apnea patients participating in a weight loss...
Conference Coverage
First RCT with aromatase inhibitor for male hypogonadism shows promise
NEW ORLEANS – In hypogonadism, an experimental aromatase inhibitor increased testosterone without reducing semen quality.
Feature
Montana named ‘best state to practice medicine’ in 2019
New York ranks last, based on WalletHub measures.
News
FDA approves Jatenzo for treatment of male hypogonadism
The oral route of administration provides an important addition to current available treatments options for men with certain hypogonadal...
Conference Coverage
Hyperglycemia drives leaky gut syndrome, inflammation
MIAMI - HbA1c strongly correlated with the influx of microbial molecules in humans. Correcting hyperglycemia prevented enteric infections and...
Conference Coverage
New postmenopausal osteoporosis guidelines emphasize patient priorities
NEW ORLEANS –
Conference Coverage
Fezolinetant looks good for hot flashes in phase 2b trial
NEW ORLEANS – Big reductions in vasomotor symptoms were seen despite a strong placebo response for this nonhormonal therapy.